A distinct natural killer (NK) cell subset, termed CLL_NK, is a precursor to effector NK phenotypes and serves as a critical immunologic marker in chronic lymphocytic leukemia (CLL), offering ...

The FDA approved an expanded access program for troculeucel, making the treatment available to patients outside clinical trials.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Researchers discovered that people carrying the APOE ε4 gene variant share a unique immune-related protein signature across ...

A new class of South Korean immunotherapy drugs is raising hopes for a breakthrough in the treatment of a rare blood cancer ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings, ...

Management of NK-cell Malignancies The appropriate therapeutic approach for NK-cell malignancies should be determined according to the following clinical subtypes: nasal NK-cell lymphoma, non ...

Salvage Treatment of NK-cell Lymphomas The treatment of patients relapsing from, or refractory to, CHOP or CHOP-like regimens is still problematic.

Researchers at the VIB-KU Leuven Center for Cancer Biology have uncovered that "natural killer" cells (NK), a type of immune cell, may actually be hindering the immune system's ability to attack ...

All of us produce a growth factor—called IL-15—which effectively protects us from cancers. Its role is to boost the production of immune cells that can rapidly detect and kill cancer cells ...

SNAP Biosciences and Monarch Therapeutics announce a licensing deal for advanced NK cell therapies using small molecule adaptors.